Pre-Open Stock Movers 12/09: (MTSC) (RCKT) (QS) Higher; (PSTI) (PLAB) (GME) Lower (more...)

December 9, 2020 9:29 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Today's Pre-Open Stock Movers:

MTS Systems Corporation (Nasdaq: MTSC) 49% HIGHER; Amphenol Corporation (NYSE: APH) (Amphenol), a leading global provider of high-technology interconnect, antenna and sensor solutions, and MTS Systems Corporation (Nasdaq: MTSC) (MTS), a leading global supplier of advanced test systems, motion simulators and precision sensors, today announced that they have entered into a definitive agreement under which Amphenol will acquire MTS for $58.50 per share in cash, or approximately $1.7 billion, including the assumption of outstanding debt and liabilities, net of cash.

Pluristem Therapeutics Inc. (Nasdaq: PSTI) 42.6% LOWER; Based on the review, the DMC concluded that the CLI study is unlikely to meet the primary endpoint by the time of the final analysis. The DMC advised the Company that the CLI study population has experienced a substantial low number of events (major amputation of the index leg or death), different from what is known in clinical medicine for the rate of these events in this patient population. The lower than anticipated event rate in the placebo group reduced the statistical power of the study to meet its primary endpoint.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) 33.4% HIGHER; announces preliminary data from its open-label, Phase 1 clinical trial of RP-A501, the Companys adeno-associated viral vector (AAV)-based gene therapy candidate expressing LAMP2B for the treatment of Danon Disease. Danon Disease is a rare X-linked inherited disorder caused by genetic mutations in the LAMP2 gene resulting in accumulation of autophagosomes and glycogen, particularly in cardiac muscle and other tissues, which ultimately leads to severe and frequently fatal cardiomyopathy. Preliminary data from patients in the low dose RP-A501 cohort showed that the gene therapy was generally well tolerated and provided early evidence of clinical benefit.

QuantumScape Corporation (NYSE: QS) 28.6% HIGHER; adds to recent gains

Curis, Inc. (NASDAQ: CRIS) 18.9% HIGHER; announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. Curis intends to grant the underwriters a 30-day option to purchase additional shares in an amount of up to 15% of the shares sold in the public offering, on the same terms and conditions. Adds to Tuesday's 355% gain.

Cardtronics plc (Nasdaq: CATM) 22.7% HIGHER; confirmed that it has received a proposal from funds managed by affiliates of Apollo Global Management, Inc. and Hudson Executive Capital LP to acquire all of the outstanding shares of the Company for $31.00 per share in cash.

Photronics, Inc. (NASDAQ: PLAB) 17.9% LOWER; reported Q4 EPS of $0.10, $0.05 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $149.3 million versus the consensus estimate of $153.87 million. Photronics, Inc. sees Q1 2021 EPS of $0.07-$0.14, versus the consensus of $0.16. Photronics, Inc. sees Q1 2021 revenue of $145-155 million, versus the consensus of $152.57 million.

Omnicell (NASDAQ: OMCL) 13.3% HIGHER; Baxter (NYSE: BAX) said to have made a takeover approach for Omnicell (NASDAQ: OMCL), according to Bloomberg

ProPhase Labs, Inc. (NASDAQ: PRPH) 12.3% HIGHER; announced that it has continued its CLIA Lab rollout with the execution of a lease for a 25,000 square foot facility in Garden City, New York. This new lab, like the Company’s first lab in Old Bridge, New Jersey, will provide a wide range of laboratory testing services for diagnosis, screening and evaluation of diseases, including COVID-19 and Respiratory Pathogen Panel (“RPP”) Molecular tests.

GameStop (NYSE: GME) 12% LOWER; reported Q3 EPS of ($0.53), $0.32 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $1 billion versus the consensus estimate of $1.09 billion.

The Lovesac Company (NASDAQ: LOVE) 11.7% HIGHER; reported Q3 EPS of $0.16, $1.04 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $74.7 million versus the consensus estimate of $66.14 million.

Delcath Systems, Inc. (NASDAQ: DCTH) 9.7% LOWER; announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.

dMY Technology Group (NYSE: DMYT) 9.6% HIGHER; Craig-Hallum initiates coverage with a Buy rating and a price target of $23.00.

Talos Energy Inc. (NYSE: TALO) 9.2% LOWER; announced today that it has commenced an underwritten public offering of 8,250,000 shares of common stock of the Company.

Ichor Holdings, Ltd. (NASDAQ: ICHR) 8.3% LOWER; commenced an underwritten public offering of 3,500,000 of its ordinary shares. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 525,000 of its ordinary shares sold in the offering at the public offering price, less underwriting commissions.

FireEye (NASDAQ: FEYE) 7.5% LOWER; was breached by suspected nation-state hackers, according to Dow Jones, citing a company blog post.

HOOKIPA Pharma Inc. (Nasdaq: HOOK) 6.8% LOWER; intends to offer and sell shares of its common stock and shares of Series A convertible preferred stock in an underwritten public offering.

Lowe's Companies, Inc. (NYSE: LOW) 5.2% HIGHER; will be introducing the Total Home strategy to further accelerate market share gains. Announces $15 billion buyback.

Bloom Energy Corp. (NYSE: BE) 5.9% LOWER; JPMorgan downgraded from Overweight to Neutral with a price target of $26.00 (from $22.00).

Guidewire Software (NYSE: GWRE) 3% LOWER; reported Q1 EPS of $0.17, $0.22 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $169.8 million versus the consensus estimate of $164.62 million. Guidewire Software sees Q2 2021 revenue of $168-172 million, versus the consensus of $169.8 million. Guidewire Software sees FY2021 revenue of $723-728 million, versus the consensus of $730 million.

SmileDirectClub, Inc. (Nasdaq: SDC) 2.2% HIGHER; secured a second patent from the United States Patent & Trademark Office (”USPTO”) for its SmileShop retail concept and digital methodology for the delivery of clear aligner treatment to consumers. The patent, U.S. Patent No. 10,861,599, further strengthens protection for SmileDirectClub’s groundbreaking method for bringing affordable, accessible oral care to more people through its telehealth platform. The patent further ensures no clear aligner competitor will be able to duplicate SmileDirectClub’s unique model for 18 years.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

JPMorgan, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers